NYSEARCA:NHWK - NYSE Arca - US42237K4094 - Common Stock - Currency: USD
0.4135
+0.03 (+8.96%)
The current stock price of NHWK is 0.4135 USD. In the past month the price decreased by -8.05%. In the past year, price decreased by -60.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.83 | 323.41B | ||
AMGN | AMGEN INC | 13.41 | 149.70B | ||
GILD | GILEAD SCIENCES INC | 14.01 | 134.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.30B | ||
REGN | REGENERON PHARMACEUTICALS | 13.36 | 63.90B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.23B | ||
ARGX | ARGENX SE - ADR | 98.17 | 35.18B | ||
ONC | BEIGENE LTD-ADR | 6.15 | 25.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.45B | ||
NTRA | NATERA INC | N/A | 22.01B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.34B | ||
BIIB | BIOGEN INC | 8.06 | 18.69B |
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 77 full-time employees. The company went IPO on 2013-07-24. Scorpius offers an array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its clinical biomanufacturing capabilities include cGMP Mammalian Cell Culture and cGMP Microbial Fermentation. Its process development includes mammalian cell culture development, cell therapy development, microbial fermentation development, downstream process development and formulation development. The company also offers bioanalytical services, analytical methods development, pre-clinical and product development services, CMC analytical support services, bioassays and analytical technologies.
NIGHTHAWK BIOSCIENCES INC
627 Davis Drive, Suite 300
Morrisville NORTH CAROLINA US
Employees: 77
Phone: 19192407133
The current stock price of NHWK is 0.4135 USD. The price increased by 8.96% in the last trading session.
The exchange symbol of NIGHTHAWK BIOSCIENCES INC is NHWK and it is listed on the NYSE Arca exchange.
NHWK stock is listed on the NYSE Arca exchange.
6 analysts have analysed NHWK and the average price target is 10.2 USD. This implies a price increase of 2366.75% is expected in the next year compared to the current price of 0.4135. Check the NIGHTHAWK BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NIGHTHAWK BIOSCIENCES INC (NHWK) has a market capitalization of 36.34M USD. This makes NHWK a Nano Cap stock.
NIGHTHAWK BIOSCIENCES INC (NHWK) currently has 77 employees.
NIGHTHAWK BIOSCIENCES INC (NHWK) has a support level at 0.37 and a resistance level at 0.44. Check the full technical report for a detailed analysis of NHWK support and resistance levels.
The Revenue of NIGHTHAWK BIOSCIENCES INC (NHWK) is expected to decline by -28.99% in the next year. Check the estimates tab for more information on the NHWK EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NHWK does not pay a dividend.
NIGHTHAWK BIOSCIENCES INC (NHWK) will report earnings on 2024-03-29, after the market close.
NIGHTHAWK BIOSCIENCES INC (NHWK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.98).
ChartMill assigns a technical rating of 1 / 10 to NHWK. When comparing the yearly performance of all stocks, NHWK is a bad performer in the overall market: 90.35% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to NHWK. NHWK has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NHWK reported a non-GAAP Earnings per Share(EPS) of -1.98. The EPS decreased by -21.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -74.32% | ||
ROE | -143.11% | ||
Debt/Equity | 0.25 |
ChartMill assigns a Buy % Consensus number of 43% to NHWK. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -16.18% and a revenue growth -28.99% for NHWK